Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase NA 3Phase 3 3Phase 2/3 2Phase 1/2 1

Status

Unknown 12Recruiting 4Completed 4Not yet recruiting 3Withdrawn 1Terminated 1Suspended 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1

Conditions

Ovarian Cancer Recurrent 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

Standard of Care 25Exercise 24Interviews as Topic 19Blood Specimen Collection 18Educational Status 13Methods 12Surgical Procedures, Operative 11Drug Therapy 11Surveys and Questionnaires 10Radiosurgery 10Specimen Handling 9Saline Solution 9Acupuncture Therapy 9Paclitaxel 8Early Intervention, Educational 8Therapeutics 7Radiotherapy 7Magnetic Resonance Spectroscopy 7Electroacupuncture 7Cryotherapy 7Resistance Training 6Preoperative Exercise 6Practice Guidelines as Topic 6Palliative Care 6Dexmedetomidine 6Control Groups 6Colonoscopy 6Carboplatin 6tislelizumab 5Sentinel Lymph Node Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase NA × Not yet recruiting × apatinib × Clear all
NCT07618546 2026-06-01

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

Henan Cancer Hospital

Phase NA Not yet recruiting
208 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07371871 2026-01-28

A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer

Anhui Provincial Cancer Hospital

Phase NA Not yet recruiting
30 enrolled
Gastrointestinal

Advanced Gastric Cancer

NCT06102707 2023-10-26

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Qilu Hospital of Shandong University

Phase NA Not yet recruiting
50 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡